Diagnosis-based risk adjustment is increasingly seen as an important tool for establishing capitation payments and evaluating appropriateness and efficiency of services provided and has become an important area of research for many countries contemplating health system reform. This paper examines the application of a risk-adjustment method, extensively validated in the United States, known as diagnostic cost groups (DCG), to a large Australian hospital inpatient data set.
The data set encompassed hospital inpatient diagnoses and inpatient expenditure for the entire metropolitan population residing in the state of New South Wales. The DCG model was able to explain 34% of individual-level variation in concurrent expenditure and 5.2% in subsequent year expenditure, which is comparable to US studies using inpatient-only data. The degree of stability and internal consistency of the parameter estimates for both the concurrent and prospective models indicate the DCG methodology has face validity in its application to NSW health data sets. Modelling and simulations were conducted which demonstrate the policy applications and significance of risk adjustment model(s) in the Australian context. This study demonstrates the feasibility of using large individual-level data sets for diagnosis-based risk adjustment research in Australia. The results suggest that a research agenda should be established to broaden the options for health system reform.
Risk adjustment and capitation
POLICY MAKERS THROUGHOUT most of the industrialised world are grappling with ways to improve the efficiency and equity of their health care systems, to contain macro-level expenditure and to make their health systems more innovative and responsive to consumer preferences. To this end, risk adjustment methods are increasingly being seen as an important policy tool for both competitive and noncompetitive population-based health care systems. 1 Risk adjustment accounts for differences in individual health risk and, hence, the expected health care resource requirements of patients. Risk adjustment can play an important role in establishing appropriate funding levels and ensuring resource allocation is made more equitable by being matched to the health care needs of the population. [1] [2] [3] [4] It can also assist in the assessment of provider performance. If the casemix adjustment is insensitive to differences in health care status of patients, providers might be penalised for treating sicker patients or be incorrectly assessed in terms of their relative efficiency in treating such patients.
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Various methods have been used for predicting resource requirements based on individual-level health risk. To date, most attention has been given to the development of models in which risk adjustment is based upon diagnostic information. 8 These methods use diagnostic information obtained from administrative data generated from patient encounters with the health system. These data are used to infer the patient' s medical problem and, from this, their likely need for health services. 4 A substantial research agenda in the development and implementation of diagnosis-based risk adjustment methods has been under way in the United States since the early 1980s and in European countries since the mid 1990s. 3, 9 Although the purpose of risk adjustment is to pursue efficiency and equity objectives, the aims differ slightly depending on whether third-party purchasers operate in a competitive or non-competitive environment. In a competitive environment where health plans can compete for enrolees, such as those in the Netherlands, Israel, Belgium and the US Medicare system for example, efficiency in the operation of the insurance markets is of critical importance. 8, 10 A fundamental consideration here is for risk adjustment to be used as the basis of individual capitation rates, and accordingly it must be able to explain variances in predictable expenditures of the individual. A good risk adjuster need not explain variances in expenditure associated with unpredictable or random events, as conventional insurance and risk-sharing arrangements are applied in such circumstances. Inadequate risk-adjusted capitation payments create incentives for health funds to exploit unpriced heterogeneity by avoiding those individuals where expected costs exceed what is paid and, conversely, selecting those enrolees where payments exceed expected costs. That is, there are perverse incentives to select good risk and avoid bad risk (ie, risk selection).
There is also growing interest in the use of individual-level data in non-competitive health systems, and research into the potential use of risk adjustment is now taking place in countries such as the UK, Canada and Spain. [5] [6] [7] In these countries, individual-level risk adjustment methods are seen as useful for devolving budgets down to smaller and less well defined geographical populations, such as primary care groups and large general practices in the UK and regional health areas in Canada, and for assessing efficiency of primary health care clinics in Spain. Consequently, methods of funding that accommodate variations in the health characteristics of individual patients are increasingly needed for equitable resource allocation across population groups and for valid measurement of performance across health care providers.
Australia operates both a predominantly publicly funded universal health insurance system through Medicare, as well as a significantly subsidised voluntary private insurance sector covering 45% of the population for private hospital care and ancillary services. Risk adjustment methods have potential relevance in the public health system for establishing capitation funding (such as in New South Wales area health services [AHS]) as well as for monitoring the performance of provider networks who provide health services for large public purchasers such as the Department of Veterans' Affairs. Importantly also, risk adjustment methods have significant relevance in the private health insurance sector for establishing prospective reinsurance arrangements in order to promote incentives for efficiency while maintaining the principles of community rating. The Australian mix of financing and service provision has made managed competition, a longer-term market-based solution aimed at integrating private health insurance into the universal framework of Medicare, a viable option for reform and, consequently, risk adjustment is of key importance.
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This paper reports on an exploratory inquiry into the Australian application of a particular risk adjustment method that has been extensively validated in the US, known as diagnostic cost groups (DCGs), to a large Australian hospital inpatient data set. The study applies the risk adjustment system software, known as DxCG, to individuallevel hospital inpatient diagnosis and expenditure data. The database is the inpatient records for 1996-97 and 1997-98 for the metropolitan regions of New South Wales.
The aims of the study were to assess the validity of the DCG methodology in the Australian context; determine the ability of the diagnostic method to predict concurrent and subsequent year expenditure; and explore the potential application and policy implications of the risk adjustment models. While there have been some previous studies [12] [13] in risk adjustment in Australia this is the first study which has applied the method to a large Australian data set. This enabled a more detailed analysis of the robustness and internal consistency of parameter estimates and allowed for particular modelling simulations to be performed in order to demonstrate the policy importance of diagnosis-based risk adjustment methods.
Methods
The DCG method begins by classifying the 15 000 ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes to one of 545 clinically similar categories known as DxGroups. The 545 DxGroups are in turn clustered into 118 condition categories (CCs) based on clinical similarity and comparable expected costs. The condition categories are organised into hierarchies (HCCs, or hierarchical coexisting conditions) to ensure that only the most expensive of closely related condition categories are assigned to an individual. A full list of the HCC category names is shown in the Appendix. The DCG/HCC system is a multiple condition model and individuals therefore can have more than one HCC allocated to them. The DCG risk adjustment model uses linear, single equation, ordinary least squares (OLS) regression methods to model expected health care expenditures of individuals using demographic and HCC (diagnosis-based) parameter estimates as explanatory variables.
The data used in this analysis were provided by the New South Wales health department (NSW Health). The data set contains hospital inpatient diagnosis and modelled inpatient expenditure data linked at the individual level over 2 years for the fiscal years 1996-97 and 1997-98. It includes the entire population residing in the catchment area of the nine metropolitan area health services in New South Wales. The data set included all episodes of public or private hospitalisation for a population of 4 836 203 and 4 882 934 for the 2 years included in the study. In 1996-97, 831 666 individuals (17.3%) were hospitalised, and in 1997-98 there were 848 454 people (17.4%) hospitalised. Costs for each hospitalisation were estimated using data from the NSW Hospital Comparison Data Book and the NSW Casemix standards for 1999-2000. For acute care, actual cost data were unavailable and costs were estimated using casemix standards based on the NSW Hospital Cost Study for 1997-98 and Version 3.1 (Australian National) Diagnosis Related Groups (DRGs). Costs for sub-and non-acute separations were estimated on the basis of beddays using data provided in the NSW hospital comparison data book -a benchmark costing framework developed by NSW Health. Numbers of non-treated patients residing in the metropolitan AHS were determined by reference to the Australian Bureau of Statistics census data.
A series of multivariable linear regressions were constructed to predict concurrent and subsequent year expenditures. Individual costs were explained by a series of dummy variables for each individual' s HCC. To validate the explanatory performance, a split sample method, similar to that used in other research studies, was used to establish model structure and to assess and validate performance. 3, 14 The model is first fitted against a sample population (ie, development sample) to establish the model structure and estimate parameter coefficients. A validation process is then undertaken whereby the model structure and coefficient estimates derived from the development sample is applied to the actual data of a second (ie, validated) sample. The explanatory capability of the "out-ofsample" fit in terms of R 2 is assessed against the original development sample. Finally, linear regression is used to determine parameter estimates for a combined model (ie, development and validated sample sets) which then forms the basis upon which subsequent predictive analysis is undertaken. Various modelling and simulation exercises were undertaken demonstrating particular policy applications of the DCG model(s), and comparisons are made with age-sex and prior cost models to highlight the importance of risk adjustment methods in a policy context. This study applied Release 5. 
Results
Since the NSW data set only contains hospital expenditures, the concurrent model was confined to developing a casemix profile for the hospitalisedonly population. A development sample of 500 000 patients was randomly selected from the hospitalised population of 831 666 with the remaining 331 336 people forming the second, or validated, sample.
Concurrent data model
The explanatory performance of various alternative model structures is summarised in Box 1. Before modifications, the development and second sample were able to explain 31.7% and 29.0% of the variation in concurrent expenditure, respectively. Several modifications were made to the concurrent model. These included, first, trimming expenditure to a per individual threshold of $50 000 to limit the effects of extreme isolated outliers. Secondly, some HCCs were combined when they were unstable (across the two sample sets) due to small population numbers (ie, HCC 040/041; 045/046; 089/090; 101/102; 105/106; 110/111). Thirdly, some HCCs were combined when they had inconsistent cost-rank ordering (HCC 006/007; 072/073; 074/075) Finally, ageinteraction terms were retrospectively introduced for a child (ie, less than 18 years old) and for the elderly (ie, greater that 64 years old) when there were more than 1000 people in the cohort and when the variable was statistically significant (at 99%). All other HCCs (including those coefficients that were statistically insignificant) remained in the model unchanged.
Box 1 shows that the cumulative effects of these three modifications led to some minor improvement in model performance with the R 2 for the development and second sample increasing to nearly identical figures of 0.345 and 0.339, respectively. Trimming the per person inpatient expenditure to $500 000 marginally increased the R whose expenditures exceeded the threshold (32 and 21 people for the development and second sample set, respectively). Combining HCCs and adding age interaction seems to have had a negligible impact upon the explanatory capabilities of the model. For comparative purposes, and as expected, applying alternative expenditure threshold trims of $250 000 and $100 000 improves the R 2 to 0.379 and 0.442, respectively. Validating the model structure by running the estimated coefficients generated from the development sample against the actual data in the validated sample shows an R 2 of 0.338 -a figure very similar to both the development and second sample sets, indicating consistent and valid fit of model structure. As expected, the diagnosisbased model is significantly better than the model with age-sex only. Including the HCC variables and other modifiers increases the R 2 for the combined data set of 831 666 from 0.039 to 0.342. The full model structure showing the parameter estimates is presented in the Appendix. Overall, the explanatory capabilities of the concurrent model are similar to US results when using inpatient data.
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Prospective model
For the prospective model, given the absence of other medical costs in the NSW data set, Year 1 inpatient diagnosis and demographic variables are used to predict Year 2 inpatient costs rather than total health costs. One difficulty this presents is the extent of the relationship between Year 1 diagnosis and Year 2 inpatient costs. Specifically, many (Year 1) acute conditions may not necessarily be good predictors of hospital expenditures for the following year. For this reason, a total of 35 HCCs from the original 118 HCC parameters were recommended for exclusion by DxCG system developers, as these categories were considered to have no a priori relationship with subsequent year hospitalisations (see Appendix for the 35 excluded HCCs).
Given potentially small population numbers for some HCCs, a stratified random sample consisting of 400 000 randomly selected hospitalised patients, together with 600 000 randomly selected non-hospitalised patients, from the 1996-97 data set was established for both the development and second sample set. The stratified development sample was then weighted in accordance with the relative proportion of hospitalised to non-hospitalised mix as reflected in the general population.
A summary of the explanatory performance of the various model structures, the R 2 , is shown in Box 2. Several modifications were made to the model structure. First, as with the concurrent model, individual-level expenditure was trimmed to a threshold of $500 000 in order to reduce the potential impact of large anomaly outliers. Second, nine HCCs with negative coefficients generated by the development sample ( for the basic model structure for the development and second sample was 0.052. The R 2 for the cross-validation was 0.052 -a figure which is the same as both the development and second model, demonstrating general soundness in the underlying model structure. For the combined population model of 2 million individuals, the R 2 for DCG/HCC models is also 0.052. The explanatory capability of the prospective model is also comparable with US results using inpatient data. The parameter estimates for the combined prospective model are shown in the Appendix. The combined model structure is used for modelling purposes which are discussed later in the paper.
As expected, reducing the expenditure threshold from $250 000 to $100 000 improves the R 2 for the weighted model from 0.054 to 0.062 respectively. An interesting result is that the DCG/HCC model has higher explanatory capabilities than the prior cost model with the latter weighted model having an R 2 of 0.040. Box 2 also shows that the R 2 for the age-sex model was 0.030.
With regard to the parameter estimates generated by the HCC/DCG model presented in the Appendix, the concurrent model demonstrated a high degree of internal consistency and stability in coefficients across the development and validated sample sets. There was strong internal consistency, with nearly all higher cost HCCs having higher estimated coefficients relative to lower cost HCCs within the same hierarchical category. Differences in parameter estimates between two sample sets are attributable to small population numbers. In both sample sets the estimated coefficients remained highly stable when they were subject to modifications, indicating that the model structure was robust. Applying the Huber-White robust estimator to correct standard errors for heteroscedasticity (to accommodate changing variances in the disturbance term of the dependent variable) only 2 HCCs were statistically insignificant but were retained in the combined model structure.
The estimated coefficients generated by the prospective model are shown in the Appendix. They did not exhibit the same degree of stability and internal consistency as the concurrent model. However, this was not unexpected as the analysis was confined to inpatient-only expenditure. In addition to the a priori exclusion of 35 HCCs, an additional 14 HCCs in the combined model generated negative coefficients and had to be constrained to zero, while a further set of 6 HCCs were combined to maintain stability and cost monotonicity. The parameter estimates across both sample sets were stable when subject to these modifications, again indicating a robust model structure. Correcting standard errors using the Huber-White robust estimator, 16 HCCs were statistically insignificant but were retained in the combined model structure. Despite the limitations of the data set the prospective model exhibited reasonable stability and internal consistency and had demonstrably higher levels of explanatory capabilities relative to both age-sex and prior cost models.
Discussion
The findings from this study suggest that the DCG methodology has validity in its application to a large population health care data set in the Australian context. The policy importance is that the risk adjustment framework can be applied either as a method for monitoring performance of area health services, determining capitation-based funding or for identifying high-cost users for case management purposes.
Monitoring efficiency of area health services
An important application of the concurrent model is to compare and explain differences in utilisation Payment and Policy patterns across area health services once adjustments have been made for health status. Box 3 shows a comparison between the mean actual expenditures for hospitalised patients and mean expected hospital expenditures based on the DCG/ HCC and age-sex concurrent model grouped by the nine AHS regions in metropolitan New South Wales. The relative index shown in Box 3 represents each region' s actual expenditure as a proportion of the average state expenditure. For example, the average actual expenditure for the hospitalised population for AHS-A was 6% above the state mean expenditure. The expected index shows the expected expenditure in the respective models as a proportion of the actual state average expenditure. From this information, a regional efficiency index can be calculated as the ratio of the actual to expected expenditure. For example, based on the DCG/HCC model the expected index for AHS-A was 1.12, which implies that, given the utilisation and age-sex profile of its population, the mean hospital expenditure for that region was expected to be 12% above the state average. However, since the actual mean expenditure was only 6% above the state mean expenditure, this implies that AHS-A has an efficiency index of 0.95. That is, AHS-A is 5 percentage points more efficient than the state average after adjusting for (diagnosis-based) health status of its hospitalised population. The efficiency indices for all the area health services based on both the DCG model and an age-sex model are shown in Box 3.
An interesting outcome shown in Box 3 is the difference between the efficiency indices generated by the DCG/HCC and age-sex demographic models. In particular, AHS-A has an efficiency index of 0.95 according to the DCG/HCC model and 1.05 according to the age-sex model predictions. There is also a significant difference in the efficiency index for AHS-G with the DCG/HCC model indicating an efficiency index of 1.11 compared with an index of 1.04 for the demographic model. There are also some noticeable differences for several other AHS regions which would translate into non-trivial differences in the budget allocation using the two algorithms.
Ostensibly, Box 3 represents the efficiency of a region to manage its hospital costs for its hospitalised population. It would of course be desirable to have medical costs incorporated into the analysis so that the performance is based on the regional health authorities' ability to manage overall patient costs including the effects of services substitution. The important feature of the above analysis is that variations in health status measures, even when aggregated at a regional level, may not be adequately captured by age-sex demographic characteristics. Diagnosis-based risk adjustment offers the potential for more refined measures of casemix adjustment of population groups. The policy implication here is that if the federal and state governments engaged in systematic reform and devolved a single stream of funding for health care services down to area service boards, then developing diagnosis-based risk adjustment methods would be a more appropriate policy tool for establishing the funding base and assessing the relative efficiency of area health services. Reliance on age-sex demographic methods results in misleading assessment of the efficiency of area health services.
Competing health insurers and risk selection
The importance of establishing adequate capitation payments so as to minimise the risk-selection incentives within a competitive environment, such as in a managed competition framework or for prospective reinsurance arrangements, is demonstrated below. A simulation exercise was conducted which treated the 9 AHS regions as competing health plans which received two types of capitated payments; one based on age-sex model predictions, and the other on DCG/HCC model predictions. Each health plan is assumed to risk-select patients based on prior cost modelling information. More specifically, each health plan is assumed to risk-select patients when the capitated payment received for an individual is greater than their predicted costs based on the prior cost information; and dump patients when losses are predicted. Profit and losses are then calculated by subtracting the actual costs incurred by individuals after risk selection from the capitation payments received by the plans.
Results reported in Box 4 show that when health plans do not engage in risk selection total profit across all 9 health plans sum to zero as total capitated payments for age-sex and DCG/HCC methods are both modelled to equal total actual costs across the entire state. However if age-sex is used as the basis for establishing capitated payments, and given zero transaction costs, health plans on average will dump around 15.6% of patients and profits totalled across the 9 health plans will increase from zero to $130.5 million (when extrapolated to the entire population of 4.8 million persons). Thus considerable incentives for risk selection exist under age-sex capitation payments (given our assumption that health plans will utilise prior cost information, which is superior to age-sex model predictions). However, if capitation payments are based on DCG/HCC model predictions, and given the relatively poorer explanatory capabilities of the prior cost model, the 9 health plans would risk incurring aggregate losses totalling $28.8 million if they attempt to risk-select based on the prior cost model. Risk selection is thus a loss making strategy and health plans would therefore be expected not to engage in such activity and instead earn zero (ie, normal) economic profits.
Box 4 also shows the extent of, and incentives for, risk selection where there are alternative transaction costs of $50 and $100 per person. These scenarios recognise that person-dumping is not costless. As expected, the extent of risk selection reduces with greater transaction costs of dumping, but the incentives to risk-select are still considerable. In the case of age-sex capitation, total absolute profits increase with greater transaction costs since fewer people are dumped (ie, more people are enrolled in total). If transaction costs rise to sufficient levels risk selection will eventually reduce to zero and normal economic profits will be earned. The above situation is of policy relevance for the Commonwealth government which is currently developing age-sex related risk adjusters for determining reinsurance arrangements for health insurers (scheduled for introduction in mid 2006). In order to underpin the community rating principle while also trying to create incentives for efficiency, health funds with "sicker" population cohorts will be prospectively reimbursed on a capitated basis through reinsurance arrangements based on the age-sex profile of their enrolled population. However if the age-sex capitated payments are inadequate to compensate health funds for having a sicker patient cohort then incentives exist to risk-select healthier patients at the expense of the sicker population. The simulation exercise presented shows quite clearly the superiority of diagnosis-based riskadjusted capitated payments over age-sex related casemix with respect to reducing the incentives for risk selection and promoting efficient thirdparty purchasing.
Similarly, if a managed competition model were contemplated in Australia, developing adequate risk adjusters is an essential prerequisite in order to establish capitated payments and minimise incentives for risk selection. As long as risk adjusters can explain the predictable component of the variation in individual-level expenditure at least as well as methods utilised by health funds then the incentives for risk selection are significantly reduced.
Identifying high cost users
Another interesting application of the prospective model is the ability to identify high cost users. The task performed in this study was to use the prospective DCG model, the prior cost model and age-sex model to generate the 20 000 highest cost users (ie, the highest 1%). Similar to other studies, 16 a comparison is then made between the three models by observing the degree of overlap between the individuals predicted to be high cost users by the respective models with the individuals who actually were high cost users in Year 2. Of the 20 000 individuals identified and predicted by the DCG/HCC model to be the highest cost users, 3004 people (15%) matched the actual 20 000 highest cost individuals. The prior cost and age-sex models were able to identify 2472 individuals (12.4%) and 1318 individuals (6.6%), respectively, who were in the highest 20 000 actual users.
Box 5 reports another result for the highest 20 000 users predicted by both the prior cost and DCG/HCC model. Interestingly, 6020 individuals were predicted in common by the two models. This represented about 30% of each model' s 20 000 highest cost users. However, this result could be used to account for more of the overall actual costs than the remaining 70% in both models.
The combined use of prior cost and diagnostic information has greater capabilities for identifying people who will be expensive in the following year. This conclusion is consistent with those reported in other similar analyses. 16 The policy implication is that diagnostic information becomes an important tool for identifying potentially high cost patients. Accordingly, early identification and intervention through timely and coordinated care offers the potential to improve health outcomes and also reduce health expenditure. Reliance on only prior cost information is a less robust method for determining high cost patients than diagnosis-based methods.
Conclusion
Research into and the application of diagnosisbased risk adjustment methods has been under way in many European countries since the mid 1990s as part of the broader approach to health care reform. Risk adjustment is increasingly being seen as an important policy tool for establishing prospective capitation payments for both competitive and non-competitive third-party purchasing health systems and to evaluate appropriateness and efficiency of services provided.
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The degree of stability and internal consistency of the estimated coefficients in the regression results for both the concurrent and prospective DCG/HCC models as well as the general explanatory performance comparable to similar overseas studies indicate DCG methodology has face validity in its application to NSW Health data sets. Findings from this exploratory study suggest that further research into the validity and potential usefulness of diagnosis-based risk adjustment methods ought to be pursued. However, further research into these methods, in the Australian context, should involve data sets with linked hospital and medical expenditure data. This will permit a full exploration of the potential capabilities associated with the use of individual-level information. To this end, the federal government has engaged in an exploratory initiative linking state hospital clinical and expenditure data with federal medical and pharmaceutical expenditure data at the individual level. Importantly also, information on prescription drugs has now become available at the individual level. Combining hospital diagnostic information with pharmaceutical information in developing risk adjustment models will permit research similar to the work undertaken in Europe and the US. [17] [18] [19] Models incorporating both inpatient and pharmaceutical information perform significantly better than inpatient-only models and represent stateof-the-art risk adjustment methodology in circumstances where out-of-hospital diagnostic information is unavailable. However, notwithstanding recent federal government initiatives, the establishment of linked patient-level data is still underdeveloped and priority needs to be given to the area. A recently published paper details how data linkage protocols in Australia can be established and pursued in a more comprehensive way.
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Australia appears to be committed to a mixed public-private federal-state system for the provision of health services, with the present system reflecting a series of ad hoc policies over time. This has led to a fragmented and uncoordinated health system characterised by perverse incentives such as cost-shifting between federal and state government jurisdictions. Further, inherent financial tensions between policies supporting the voluntary private insurance sector and those supporting the universal health system have not been addressed since the introduction of Medicare, leading to perennial structural instability.
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It is also important to note that the Productivity Commission in its recent review of the National Competition Policy (NCP) specifically highlighted health care as a "prime candidate" for a nationally coordinated approach to health system reform and has called for a national independent public inquiry into Australia' s health care system akin to the Hilmer inquiry that preceded the NCP.
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The development and use of individual-level risk adjustment methods make possible the consideration of reform options such as capitated single fund-holding to area health authorities or fund-holders; the development of prospective reinsurance arrangements for health insurers; as well as more encompassing competition-based reforms, such as managed competition. Such models could offer possible solutions to the inherent problems currently confronting the Australian health care system. 1, 11, 23 This study demonstrates the feasibility of utilising very large individual-level linked data sets for risk adjustment research in Australia, and the results pre-sented suggest that such a research agenda should now be undertaken to underpin the options for system reform. The letter X denotes the 35 HCCs that were originally recommended for exclusion from the prospective model by DxCG system developers. In addition to the excluded HCCs an additional 16 HCCs had negative coefficients which were subsequently constrained to zero. Age interaction terms in the concurrent model are denoted as CHCC for children under 18 and EHCC for the elderly over 65 years followed by the numeric category consistent with the general HCC categories.
